Skip to main content
SpringerLink
Log in

Planning Bioequivalence Studies of Drugs with Narrow Therapeutic Indices

  • Drugs
  • Published:
Pharmaceutical Chemistry Journal Aims and scope

The principles for assessing therapeutic equivalence based on bioequivalence studies as accepted in Russia are significantly different from those adopted abroad, in particular with respect to drugs with narrow therapeutic indices (NTI). Certification of these drugs based on bioequivalence studies with commonly recognized limits is unacceptable in practice because drugs in this concentration range can cause serious adverse side effects and be more dangerous than the reference drug. The situation becomes especially critical when the reference drug is replaced by a generic. This circumstance creates the need to develop stricter regulations for NTI drugs. This article analyzes possible approaches to planning bioequivalence investigations for NTI drugs as adopted by leading world regulatory institutions in order to harmonize them with bioequivalence studies of NTI drugs in the Russian Federation. General recommendations for planning bioequivalence studies of NTI drugs were formulated based on the analysis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. V. G. Kukes and D. Berry (eds.), Therapeutic Drug Monitoring: A Tool of Personalized Medicine [in Russian], International Association of Clinical Pharmacologists and Pharmacists Press, Moscow (2013).

    Google Scholar 

  2. Guidance on Bioavailability and Bioequivalence Studies for Orally Administered Drug Products – General Considerations, US Food and Drug Administration [internet]; [cited Jul. 20, 2016]; http://www.fda.gov/ohrms/dockets/ac/03/briefing/3995B1_07_GFI-BioAvail-BioEquiv.pdf

  3. Immediate Release Solid Oral Dosage Forms. Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation, US Food and Drug Administration [internet]; [cited Jul. 20, 2016]; http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm-070636.pdf

  4. Draft Guidance on Warfarin Sodium, US Food and Drug Administration [internet]; [cited Jul. 20, 2016]; http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM201283.pdf

  5. Draft Guidance on Dabigatran Etexilate Mesylate, US Food and Drug Administration [internet]; [cited Jul. 20, 2016]; http://www.fda.gov/downloads/Drugs/GuidanceCompliance-RegulatoryInformation/Guidances/UCM308030.pdf

  6. Investigation of Bioequivalence (CPMP / EWP / QWP / 1401 /98 Rev. 1), European Medicines Agency [internet]; [cited Jul. 20, 2016]; http://www.ema.europa.eu/docs/en_GB/document_library/contacts/not_yet_available.pdf

  7. Comparative Bioavailability Standards: Formulations Used for Systemic Effects, Health Canada [internet]; [cited Jul. 20, 2016]; http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/bio/gd_standards_ld_normeseng.php

  8. Guideline for Bioequivalence Studies for Formulation Changes of Oral Solid Dosage Forms, Pharmaceutical and Food Safety Bureau [internet]; [cited Jul. 20, 2016]; http://www.nihs.go.jp/drug/be-guide(e)/form/GL-E_120229_shohou.pdf

  9. Bioequivalence Study Rules for Drugs of the Eurasian Economic Union (version 2 dated Feb. 20, 2015) [internet]; [cited Jul. 20, 2016]; http://www.eurasiancommission.org/ru/act/texnreg/deptexreg/konsultComitet/Documents/%D0%9F%D1%80%D0%B0%D0%B2%D0%B8%D0%BB%D0%B0%20%D0%91%D0%AD%D0%98%20%D0%B8%D1%82%D0%BE%D0%B3%2020.02.2015%20%D0%BD%D0%B0%20%D1%81%D0%B0%D0%B9%D1%82.pdf

  10. A. N. Mironov (ed.), Handbook for Drug Evaluation [in Russian], Vol. 1, Grif I K, Moscow (2013), pp. 174 – 215.

    Google Scholar 

  11. D. P. Romodanovskii, T. V. Eremenkova, M. A. Dranitsyna, et al., Vedom. NTsESMP, 4, 5 – 10 (2015).

    Google Scholar 

  12. A. S. Smirnov, A. Shnaider, M. Yu. Frolov, and V. I. Petrov, Khim.-farm. Zh., 48(5), 3 – 10 (2014); Pharm. Chem. J., 48(5), 303 – 309 (2014).

Download references

Author information

Authors and Affiliations

  1. Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Public Health of the Russian Federation, Moscow, 127051, Russia

    D. P. Romodanovskii, D. V. Goryachev, Yu. V. Olefir & N. D. Bunyatyan

Authors
  1. D. P. Romodanovskii
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. V. Goryachev
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yu. V. Olefir
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. D. Bunyatyan
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 50, No. 12, pp. 42 – 45, December, 2016.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Romodanovskii, D.P., Goryachev, D.V., Olefir, Y.V. et al. Planning Bioequivalence Studies of Drugs with Narrow Therapeutic Indices. Pharm Chem J 50, 814–816 (2017). https://doi.org/10.1007/s11094-017-1538-y

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11094-017-1538-y

Keywords

Search

Navigation